Fibroblast Activation Protein α–Directed Imaging and Therapy of Solitary Fibrous Tumor
Journal of Nuclear Medicine · 2024-02 · 65 (2) · 252-257
DOI: 10.2967/jnumed.123.266411 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 04.01.2024. Verfasst von Rainer Hamacher und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany; rainer.hamacher@uk-essen.de. Hauptthemen laut MEDLINE: Solitary Fibrous Tumors, Quinolines, Membrane Proteins, Endopeptidases. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Fibroblast activation protein α (FAPα) is expressed at high levels in several types of tumors. Here, we report the expression pattern of FAPα in solitary fibrous tumor (SFT) and its potential use as a radiotheranostic target.
Methods
We analyzed FAPα messenger RNA and protein expression in biopsy samples from SFT patients using immunohistochemistry and multiplexed immunofluorescence. Tracer uptake and detection efficacy were assessed in patients undergoing clinical 68Ga-FAPα inhibitor (FAPI)-46 PET,18F-FDG PET, and contrast-enhanced CT. 90Y-FAPI-46 radioligand therapy was offered to eligible patients with progressive SFT.
Results
Among 813 patients and 126 tumor entities analyzed from the prospective observational MASTER program of the German Cancer Consortium, SFT (n = 34) had the highest median FAPα messenger RNA expression. Protein expression was confirmed in tumor biopsies from 29 of 38 SFT patients (76%) in an independent cohort. Most cases showed intermediate to high FAPα expression by immunohistochemistry (24/38 samples, 63%), which was located primarily on the tumor cell surface. Nineteen patients who underwent 68Ga-FAPI-46 PET imaging demonstrated significantly increased tumor uptake, with an SUVmax of 13.2 (interquartile range [IQR], 10.2), and an improved mean detection efficacy of 94.5% (SEM, 4.2%), as compared with 18F-FDG PET (SUVmax, 3.2 [IQR, 3.1]; detection efficacy, 77.3% [SEM, 5.5%]). Eleven patients received a total of 34 cycles (median, 3 cycles [IQR, 2 cycles]) of 90Y-FAPI-46 radioligand therapy, which resulted in disease control in 9 patients (82%). Median progression-free survival was 227 d (IQR, 220 d).
Conclusion
FAPα is highly expressed by SFT and may serve as a target for imaging and therapy. Further studies are warranted to define the role of FAPα-directed theranostics in the care of SFT patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany; rainer.hamacher@uk-essen.de.
- German Cancer Consortium, Partner site University Hospital Essen, Essen, Germany.
- Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany.
- Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, Germany.
- Division of Solid Tumor Translational Oncology, German Cancer Consortium (Partner Site Essen) and German Cancer Research Center, Heidelberg, Germany.
- Department of Translational Medical Oncology, National Center for Tumor Diseases, Heidelberg and German Cancer Research Center, Heidelberg, Germany.
Zitieren
APA
Hamacher, R., Pabst, K. M., Cheung, P. F., Heilig, C. E., Hüllein, J., Liffers, S. T., Borchert, S., Costa, P. F., Schaarschmidt, B. M., Kessler, L., Miera, M. A., Droste, M., Akbulut, M., Falkenhorst, J., Zarrad, F., Kostbade, K., Mavroeidi, I. A., Glimm, H., Umutlu, L., …, & Fendler, W. P. (2024). Fibroblast Activation Protein α–Directed Imaging and Therapy of Solitary Fibrous Tumor. Journal of Nuclear Medicine, 65(2), 252-257. https://doi.org/10.2967/jnumed.123.266411
Vancouver
Hamacher R, Pabst KM, Cheung PF, Heilig CE, Hüllein J, Liffers ST, et al. Fibroblast Activation Protein α–Directed Imaging and Therapy of Solitary Fibrous Tumor. Journal of Nuclear Medicine. 2024;65(2):252-257. doi:10.2967/jnumed.123.266411
BibTeX
@article{Hamacher2024,
author = {Hamacher, Rainer and Pabst, Kim M and Cheung, Phyllis F and Heilig, Christoph E and Hüllein, Jennifer and Liffers, Sven-Thorsten and Borchert, Sabrina and Costa, Pedro Fragoso and Schaarschmidt, Benedikt M and Kessler, Lukas and Miera, Monika A and Droste, Margret and Akbulut, Merve and Falkenhorst, Johanna and Zarrad, Fadi and Kostbade, Karina and Mavroeidi, Ilektra A and Glimm, Hanno and Umutlu, Lale and Schuler, Martin and Hübschmann, Daniel and Bauer, Sebastian and Fröhling, Stefan and Herrmann, Ken and Siveke, Jens T and Schildhaus, Hans-Ulrich and Fendler, Wolfgang P},
title = {Fibroblast Activation Protein α–Directed Imaging and Therapy of Solitary Fibrous Tumor},
journal = {Journal of Nuclear Medicine},
year = {2024},
volume = {65},
number = {2},
pages = {252--257},
doi = {10.2967/jnumed.123.266411}
}
EUVIMED